Lucence Diagnostics LiquidHallMark
Lucence Diagnostics launched the LiquidHallMark blood test for detecting multiple cancer-related mutations and viral targets for clinical use in Asia. Physicians can use the test to select targeted therapies and to monitor treatment response. The liquid biopsy panel identifies clinically relevant genomic alterations including somatic mutations, microsatellite instability, and viral DNA from ctDNA in blood. It was developed for cancers that are particularly prevalent in Asia, such as breast, colon, lung, and nasopharyngeal cancers. The test is based on Lucence's proprietary technology called AmpliMark that has sensitivity and specificity of up to 99.9 percent, the company said.